Peter Reaven, MD, on Glucose Variability and Vascular Disease Outcomes

In this podcast, Peter Reaven, MD, discusses the effects of glucose variability on vascular disease outcomes, the results of the ACCORD and VADT trials, and how the trials' results have impacted clinical practice over the years.

Peter Reaven, MD, is a professor of clinical medicine at the University of Arizona, the director of the Diabetes Program, and an adjunct research professor at Arizona State University in Phoenix, Arizona.

Additional Resources:

  • Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709-728.
  • Duckworth, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
  • Gotto AM, Bailey K, Gohdes D, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
  • Zhou JJ, Koska J, Bahn G, Reaven P. Glycaemic variation is a predictor of
    all-cause mortality in the Veteran Affairs Diabetes Trial. Diab Vasc Dis Res.
  • Zhou JJ, Schwenke DC, Bahn G, Reaven P; VADT Investigators. Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018;41(10):2187-2194.